focus -WSS

focus

author：focus 2025-09-30 00:51:40 - browse：8

Illustration of a laptop on top of a TV with a hand sticking out, holding a newspaper. -- coverage from STAT — Adobe

WASHINGTON – If you live in this city, you’re probably awash in pharmacy benefit manager ads — whether you’re listening to an NPR podcast, reading the New York Times, streaming “Yellowstone,” or watching the U.S. Open Golf Championships. It doesn’t matter if it’s 5 a.m., primetime, or 11 p.m.; in between ads for dog joint supplements and the “Barbie” movie, you will inevitably learn about these middlemen of the prescription drug market.

Ads eviscerating and glorifying PBMs have been around for years. But they’ve intensified over the past three months as Congress scrutinizes PBMs’ role in shaping high drug prices. Over a half-dozen U.S. House and Senate Committees have started investigating PBMs, advancing bipartisan legislation to increase transparency in the industry; ban PBMs from charging more for a drug than what they pay (and pocketing the difference); and require them to pass all fees, rebates, and other payments they receive to insurers.

Lobbying groups have responded to this legislative push with dueling campaigns in the court of public opinion. On one side is the Pharmaceutical Care Management Association, the trade association representing PBMs, which argues that pharmaceutical companies are responsible for high drug prices. On the other side is the industry group PhRMA, which points the finger right back, saying that PBMs are really to blame. Both trade associations have launched ad campaigns worth millions of dollars, blanketing TV, radio, social media, print, and beyond.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： Eli Lilly buys Point Biopharma in radiopharmaceuticals play

WSS

Histogen: Failed biotech offers rare public look inside

Van's Gluten Free Original Waffles recalled for possible wheat allergen

4 killed, 7 hurt in mass shooting at July 4 block party in Louisiana; no arrests made

Listen: Biogen's messy board & Laronde's data problem

PhRMA sues HHS over Medicare drug price negotiation

4th of July breaks record for highest global temperature ever measured

explore

focus

focus

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Russia says it foiled Ukrainian drone attack on Moscow as Kyiv's counteroffensive grinds on

Peter Hotez and the public health issue of online harassment

VC firm General Catalyst wants to buy a health system

Medical records are filled with copy

3 questions for the future of Biden's cancer moonshot

Medical records are filled with copy

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

Affirmative action in medical school literally saved lives

Option Care buys Amedisys in $3.6 billion home care deal

leisure time

Did the public have the right to know Arthur Ashe had AIDS?

Australia's humpback populations rebound raising hopes of marine scientists

Physician executives need more than on

Grail is spending more than ever lobbying Congress

RaDonda Vaught case: a double standard for nurses, physicians

These geoengineering technologies could help combat the climate crisis, scientists say

leisure time

hotspot

explore

focus